Clinical risk factors for invasive aspergillosis

Medical Mycology

Volumn 49, Issue SUPPL. 1, 2011, Pages

  Baddley, John W ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Aspergillus; clinical risk factors; invasive aspergillosis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTINEOPLASTIC AGENT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; COTRIMOXAZOLE; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOTRANSPLANTATION; ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; ASPERGILLUS; AUTOTRANSPLANTATION; BRONCHIOLITIS OBLITERANS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; FUNGAL COLONIZATION; FUNGUS SPORE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTENSIVE CARE UNIT; INVASIVE ASPERGILLOSIS; IRON OVERLOAD; ISCHEMIA; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY FAILURE; LIVER FAILURE; LUNG TRANSPLANTATION; LYMPHOCYTOPENIA; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; POSTOPERATIVE INFECTION; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REOPERATION; REPERFUSION INJURY; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RISK FACTOR; T CELL DEPLETION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ASPERGILLOSIS; ASPERGILLUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INTENSIVE CARE UNITS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

ASPERGILLUS;

EID: 79952675064     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.505204     Document Type: Conference Paper

References (57)

1. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-366. (Pubitemid 32173620)
2. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415. (Pubitemid 34851833)
3. Rello J, Esandi ME, Mariscal D, et al. Invasive pulmonary aspergil-losis in patients with chronic obstructive pulmonary disease: report of eight cases and review. Clin Infect Dis 1998; 26:1473-1475. (Pubitemid 28270191)
4. Vandewoude K, Blot S, Benoit D, et al. Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality. Acta Clinica Belgica 2004; 59: 251-257. (Pubitemid 40029482)
5. Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin N America 2002; 16: 875-894. (Pubitemid 35477517)
6. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007; 67: 1567-1601. (Pubitemid 47267298)
7. Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007; 139: 519-531. (Pubitemid 350043811)
8. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin N America 2003; 17: 113-134. (Pubitemid 36514573)
9. Vonberg RP, Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect 2006; 63: 246-254. (Pubitemid 43812196)
10. Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 16: 475-482. (Pubitemid 34155525)
11. Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007; 110: 1303-1306. (Pubitemid 47435602)
12. Altes A, Remacha AF, Sarda P, et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant 2004; 34: 505-509. (Pubitemid 39264040)
13. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45: 205-216. (Pubitemid 47044802)
14. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 2007; 30: 782-800. (Pubitemid 351194841)
15. Guinea J, Torres-Narbona M, Gijon P, et al. Pulmonary aspergillo-sis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 2009; Nov 10 (e-pub ahead of print).
16. Denning DW. Aspergillosis in 'nonimmunocompromised'critically ill patients. Am J Resp Crit Care Med 2004; 170: 580-581. (Pubitemid 39202196)
17. Pasqualotto AC, Denning DW. Post-operative aspergillosis. Clin Microbiol Infect 2006; 12: 1060-1076. (Pubitemid 44467631)
18. Jensen J, Guinea J, Torres-Narbona M, Munoz P, et al. Post-surgical invasive aspergillosis: an uncommon and under-appreciated entity. J Infect 2010; 60: 162-167.
19. Holding KJ, Dworkin MS, Wan PC, et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and adolescent spectrum of HIV disease project. Clin Infect Dis 2000; 31: 1253-1257. (Pubitemid 32295458)
20. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008; 83: 181-194. (Pubitemid 351303102)
21. Marr KA, Carter RA, Boeckth M, Corey L. Invasive aspergillosis in alogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366. (Pubitemid 35429674)
22. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or f ucon-azole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347. (Pubitemid 46148776)
23. Girmenia C, Barosi G, Aversa F, et al. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis 2009; 49: 1226-1236.
24. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-1466. (Pubitemid 27225051)
25. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-1050.
26. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917. (Pubitemid 34229758)
27. Martino R, Pinana JL, Parody R, et al. Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplant 2009; 44: 749-756.
28. Ascioglu S, Rex JH, de Pauw B, et al. Def ning opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14. (Pubitemid 33152659)
29. Singh N, Avery RK, Munoz P, et al. Trends in risk prof les for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36: 46-52. (Pubitemid 36099096)
30. Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003; 75: 2023-2029. (Pubitemid 36793286)
31. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol 2007; 45: 305-320. (Pubitemid 46839801)
32. Singh N, Husain S. Invasive aspergillosis in solid organ transplant recipients. AmJ Transplant 2009; 9: S180-191.
33. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999; 78: 123-138. (Pubitemid 29153028)
34. Fortun J. Infections related to intravascular devices used for infusion therapy. Enfermedades Infecciosas Microbiol Clin 2008; 26: 168-174. (Pubitemid 351416490)
35. Kubak BM. Fungal infection in lung transplantation. Transpl Infect Dis 2002; 4(Suppl. 3): 24-31. (Pubitemid 34832433)
36. Munoz P, Alcala L, Sanchez Conde M, et al. The isolation of Asper-gillusfumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis. Transplantation 2003; 75: 326-329. (Pubitemid 36222956)
37. Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergil-losis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41: 52-59. (Pubitemid 40863744)
38. Meersseman W, Vandecasteele SJ, Wilmer A, et al. Invasive aspergil-losis in critically ill patients without malignancy. Am J Resp Crit Care Med 2004; 170: 621-625. (Pubitemid 39202203)
39. Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemio-logical, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43: 577-584. (Pubitemid 44267116)
40. Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Resp Crit Care Med 2008; 177: 27-34.
41. Heinemann S, Symoens F, Gordts B, Jannes H, Nolard N. Environmental investigations and molecular typing of Aspergillus f avus during an outbreak of postoperative infections. J Hosp Infect 2004; 57: 149-155. (Pubitemid 38745428)
42. Ader F, Nseir S, Le Berre R, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect 2005; 11: 427-429. (Pubitemid 40744388)
43. Trof RJ, Beishuizen A, Debets-Ossenkopp YJ, Girbes AR, Groeneveld AB. Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med 2007; 33: 1694-1703. (Pubitemid 47476659)
44. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine 2000; 79: 250-260. (Pubitemid 30616973)
45. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005; 9: 191-199.
46. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised def nitions of invasive fungal disease from the European Organization for Research and Treatment of cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
47. Bobba RK, Arsura EL. Aspergillus infection in a hospitalised veteran population. Clin Microbiol Infect 2004; 10: 679. (Pubitemid 39077063)
48. Rodrigues J, Niederman MS, Fein AM, Pai PB. Nonresolving pneumonia in steroid-treated patients with obstructive lung disease. Am J Med 1992; 93: 29-34.
49. Tong KB, Lau CJ, Murtagh K, Layton AJ, Seifeldin R. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups. Int J Infect Dis 2009; 13: 24-36.
50. Miller WT, Jr., Sais GJ, Frank I, et al. Pulmonary aspergillosis in patients with AIDS. Clinical and radiographic correlations. Chest 1994; 105: 37-44. (Pubitemid 24029073)
51. Denning DW, Follansbee SE, Scolaro M, et al. Pulmonary aspergillo-sis in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324: 654-662.
52. Wallace JM, Lim R, Browdy BL, et al. Risk factors and outcomes associated with Identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group. Chest 1998; 114: 131-137. (Pubitemid 28337373)
53. Pursell KJ, Telzak EE, Armstrong D. Aspergillus species colonization and invasive disease in patients with AIDS. Clin Infect Dis 1992; 14: 141-148.
54. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-1265. (Pubitemid 38608568)
55. Filler SG, Yeaman MR, Sheppard DC. Tumor necrosis factor inhibition and invasive fungal infections. Clin Infect Dis 2005; 41: S208-212. (Pubitemid 41022093)
56. Manz M, Beglinger C, Vavricka SR. Fatal invasive pulmonary aspergillosis associated with adalimumab therapy. Gut 2009; 59: 149.
57. Salavert M, Bastida G, Peman J, Nos P. Opportunistic co-infection in a patient with Crohn's disease during inf iximab (anti-TNFalpha) therapy. Rev Iberoam Micol 2009; 26: 213-217.